



Alferon N® (Interferon Alfa-n3)

Last Review Date: August 1, 2019

Number: MG.MM.PH.xxx

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Alferon N (interferon alfa-n3) is indicated for the intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 years of age or older

Length of Authorization

Coverage will be provided for 8 weeks. Coverage may be renewed after 3 months after the initial 8 week course.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 160 billable units per 56 days

I. INITIAL APPROVAL CRITERIA

Alferon N may be considered medically necessary if one of the below conditions are met AND use is consistent with the medical necessity criteria that follows:

1. Condylomata acuminata

- Patient must be 18 years of age and older
- Patient must have a diagnosis of refractory or recurring external condylomata acuminata
- Patient must have an adequate trial and failure of a chemical agent (podophyllin, trichloroacetic acid, or 5-fluoruracil epinephrine gel) AND imiquimod with an inadequate

response or significant side effects/toxicity or must have a contraindication to these therapies (Step protocol not mandated for Medicare members)

Limitations/Exclusions

N/A

II. RENEWAL CRITERIA

All prior authorization renewals are reviewed on a case-by-case basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended for an additional 2-month course based upon chart documentation from the prescriber that the member's condition has recurred and requires additional treatment.

Dosage/Administration

Indication	Dose
Condylomata acuminata	– INTRALESIONAL injection of 0.05 mL (250,000 units)/wart twice weekly for up to 8 wk; MAX 0.5 mL/treatment session

Applicable Procedure Codes

J9215	Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 IU
-------	---

Applicable NDCs

54746-0001-01	vial, 1 ml Interferon Alfa-N3 (Human) (Murine) (Avian) 5,000,000U/1mL, Solution for injection
---------------	---

Applicable Diagnosis Codes

ICD-10	ICD-10 Description
A63.0	A63.0 Anogenital (venereal) warts

References

- 1) Product Information: ALFERON N^(R) injection, interferon alfa N3 injection. Hemispherx Biopharma Inc, Philadelphia, PA, 2019.
- 2) Clinical Pharmacology Elsevier Gold Standard. 2019.
- 3) Micromedex[®] Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2019.